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Summary
Objective: Gene encoding aldosterone synthase gene (CYP11B2), has been suggested to 
contribute to stroke. The present study was designed to investigate whether common 
functional polymorphism - 3 4 4 0 T  (rsl79998) of the CYP11B2 gene is associated with 
ischemic stroke (IS) and intracerebral hemorrhage (ICH) in a Russian population.
Methods: A total 936 unrelated subjects (446 ischemic stroke, 57 hemorrhagic stroke patients 
and 433 healthy controls) from Central Russia were recruited for this study. DNA samples 
from all study participants were genotyped for the CYP11B2 gene polymorphism through 
TaqMan assay.
Results: No differences in both CYP11B2 allele and genotype frequencies were found 
between entire patients and control groups. The analysis stratified by stroke subtype and 
gender was also failed to reveal the association between -344C>T polymorphism and stroke 
susceptibility. However, the -344TT genotype showed an association with increased 
prothrombin time in ICH patients (p=0.01).
Conclusion: Increased aldosterone levels in carriers of the -344TT genotype directly affect 
the coagulation system in ICH patients, however, the mechanisms, by which aldosterone is 
associated with an increased prothrombin time are not understood.
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INTRODUCTION
Stroke is a complex multifactorial disorder 
with high prevalence worldwide(8). Renin- 
angiotensin aldosterone system (RAAS) 
plays a major role in vascular homeostasis 
and genes of the RAAS are shown to be 
attractive candidates of stroke 
susceptibility(4). Aldosterone, a key player 
of this system, is involved in the regulation 
of water and electrolyte homeostasis. The 
biosynthesis of aldosterone is determined 
by enzyme aldosterone synthase 
(CYP11B2)(11). It has been found that a 
common polymorphism -344C>T in the 
promoter region of the CYP11B2 gene is 
associated with higher aldosterone 
synthase activity and enhanced aldosterone 
production(3). Several studies have been 
done so far to investigate the role of 
CYP11B2 -344C>T polymorphism in the 
pathogenesis of the pathogenesis of 
ischemic stroke (IS), but their results were 
inconsistent^’5,11}, thereby requiring further 
investigation in ethnically distinct 
populations of the world. In the meantime, 
no studies have investigated the 
contribution of the CYP11B2 gene 
polymorphism to the risk of intracerebral 
hemorrhage (ICH). The present study was 
designed to investigate the relationship 
between the -344C>T polymorphism of 
the CYP11B2 gene with the risk of IS and 
ICH in Russian population and to evaluate 
the impact of the polymorphism on the 
blood coagulation and lipid parameters.
MATERIAL AND METHODS
The study was approved by Ethical Review 
Committee of Kursk State Medical 
University. A total 936 Russian unrelated 
subjects from Central Russia 
(predominantly from Kursk region) were 
included in the study. The study population 
included 433 healthy subjects with normal 
blood pressure and 503 stroke patients 
(446 ischemic stroke and 57 patients with 
intracerebral hemorrhage) recruited at the 
Regional Vascular Center of Kursk 
Regional Clinical Hospital and Neurology
Clinics of Kursk Emergency Medicine 
Hospital over two periods: between 2007 
and 2010(14), and between 2012 and 2013. 
The mean age of stroke patients (266 
males, 237 females) was 61.07±10.09 
years; the mean age of the healthy controls 
(236 mails, 197 females) was 61.72±8.02 
years. The control subjects were enrolled 
based on having no history of any 
cardiovascular diseases and normal blood 
pressure. Diagnosis of cerebral stroke was 
verified by computed tomography (CT) or 
magnetic resonance imaging (MRI) of the 
brain. Patients with subarachnoid 
hemorrhages were not included in the 
study. Genomic DNA was isolated from 
peripheral blood samples using a standard 
phenol/chloroform procedure. The 
polymorphism C-344T (rs 179998) was 
genotyped through a TaqMan SNP 
Genotyping Assay (Applied Biosystems, 
USA) on the CFX96 s case/control status 
and re-genotyping of about 5% of 
randomly selected samples yielded 100% 
reproducibility. The total cholesterol (TC) 
and triglycerides (TG) levels were 
measured by enzymatic method on the 
automatic biochemical analyzer «Flexor 
XL» (Vital Scientific, the Netherlands). 
The prothrombin time (PT), activated 
partial thromboplastin time (APTT) and 
international normalized ratio (INR) were 
analyzed by the clotting test on the 
automatic coagulation analyzer «STA 
Compact» (Roche Diagnostics, 
Switzerland). The association between the 
polymorphism and hypertension risk was 
estimated by odds ratio (OR) with 95% 
confidence interval (Cl) using 
unconditional logistic regression. The 
biochemical parameters were tested for 
normality using the Kolmogorov-Smimov 
test. The Kruskal-Wallis test was applied 
to assess the relationship between the 
CYP11B2 gene polymorphism and 
biochemical parameters. The statistical 
significance was established at P < 0.05. 
Statistical calculations were performed 
with STATISTICA for Windows 8.0
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(StatSoft Inc; Tulsa, OK, USA)/Real-Time 
PCR Detection System (Bio-Rad 
Laboratories, USA). The genotyping 
results were scored by two independent 
investigators blindly to the patient
RESULTS
The CYP11B2 genotype frequencies were 
in agreement with Hardy-Weinberg 
equilibrium (HWE) in both patients and 
control groups (p>0.05). The genotype and 
allele frequencies are shown in Table 1. As 
can be seen from Table 1, no significant 
difference in allele and genotype 
frequencies was observed between the 
study groups. The analysis stratified by the 
type of stroke (i.e. ischemic stroke, 
intracerebral hemorrhage) has not revealed 
the association between the CYP11B2 
gene and susceptibility to these 
pathogenetic variants of stroke (Table 1). 
Moreover, the analysis stratified by gender 
was also failed to reveal the association of 
the CYP11B2 gene polymorphism and 
stroke subtypes (data not shown). The 
distribution of blood coagulation and lipid 
metabolism parameters in the carriers of 
the CYP11B2 genotypes is presented in 
Table 2. The Kolmogorov-Smirnov test
was done to test biochemical parameters 
for normality. All biochemical parameters 
showed a screw from the normal 
distribution (P<0.01), excepting TC level. 
For this reason, we preferred the Kruskal- 
Wallis test over ANOVA to indicate the 
association between the CYP11B2
genotypes and biochemical parameters. 
The distribution of biochemical parameters 
of lipid metabolism and coagulation in 
stroke persons stratified by the CYP11B2 
genotypes is shown in Table 2. Patients 
with intracerebral hemorrhage possessing - 
344TT genotypes have higher PT levels 
(5.2) than those in carriers of genotypes - 
344CT (11.77) and -344CC (10.53). Figure 
1 shows a significant association (p=0.01) 
between the -3 4 4 0 T  polymorphism of the 
CYP11B2 gene and prothrombin time in 
patients with intracerebral hemorrhage. As 
can be seen from Table 2, CS patients with 
the -344CC genotype have slightly higher 
TC concentration (5.5) in comparison with 
heterozygous -344CT (5.2) and
homozygous -344TT genotypes (5.1). We 
also observed that CS patients with variant 
genotype -344TT have a higher INR (1.0) 
in comparison with patients with genotypes 
-344CT and -344CC (P=0.08).
Table 1: Allele and genotype frequencies of polymorphism -344C/T of the CYP11B2 gene in patients and controls
CYP11B2 allele and genotype 
frequencies
CS patients 
(n=503)
n (% f
Controls 
(n=433) 
n (%)'
T
(P)2
OR
(95% Cl)3
Entire group
Allele frequencies
-344C 0,516 0,514 0,01 0,99
-344T 0,484 0,486 (0,93) (0,83-1,19)
Genotype frequencies
-344CC 134 (26,6) 121 (27,9) 0,20 (0,65) 1,07 (0,80-1,42)
-344CT 251 (49,9) 203 (46,9) 0,85 (0,36) 1,13 (0,87-1,46)
-344TT 118(23,5) 109 (25,2) 0,37 (0,54) 0,91 (0,68-1,23)
Ischemic Stroke Patients (n=446) and Controls (n=433)
Allele frequencies
-344C 0,506 0,514 0,12 1,03
-344T 0,494 0,486 (0,73) (0,86-1,25)
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Genotype frequencies
-344CC 113 (25,3) 121 (27,9) 0,77 (0,38) 1,14 (0,85-1,54)
-344CT 225 (50,4) 203 (46,9) 1,12 (0,29) 1,15 (0,89-1,50)
-344TT 108(24,2) 109(25,2) 0,11 (0,74) 0,95 (0,70-1,29)
Hemorrhagic Stroke Patients (n=57) and Controls (n=433)
Allele frequencies
allele-344C 0,596 0,514 2,76 0,72
allele-344T 0,404 0,486 (0,10) (0,48-1,06)
Genotype frequencies
-344CC 21 (36,8) 121 (27,9) 1,94 (0,16) 0,66 (0,37-1,18)
-344CT 26 (45,6) 203 (46,9) 0,03 (0,86) 0,95 (0,55-1,65)
-344TT 10 (7,5) 109 (25,2) 1,59 (0,21) 0,63 (0,31-1,29)
1 Absolute number and percentage of individuals with particular genotype;
2 Chi-square statistics with Yates ’ correction and (df= 1);
3 Odds ratio with 95% confidence intervals
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Figure 1: The distribution o f  the prothrom bin time (PT) in pa tien ts with intracerebral hemorrhage stratified  
by the CYP11B2 genotypes
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Table 2: The distribution of biochemical parameters of lipid metabolism and coagulation in stroke persons stratified by the CYP11B2 genotypes
Median, Lower and Upper Quartiles
TC, mmol/L TG, mmol/L PT, seconds APTT, seconds INR
c s IS HS CS IS HS CS IS HS c s IS HS CS IS HS
-344CC 5.5 (4.3- 5.5 (4.3- 5.1 (4.5- 1.3 (1.1- 1.4 (1.2- 1.2 (1.0- 10.79 10.79 10.53 34,75 34.95 30.9 0.97 0.97 0.96
6.2) 6.3) 5.8) 1.8) 1.8) 1.2) (10.14- (10.14- (10.14- (29.0- (28.90- (29.0- (0.9-1.2) (0.9- (0.90-
13.13) 13.13) 13.0) 37.80) 38.05) 35.0) 1.03) 1.0)
-344CT 5.2 (4.4- 5.2 (4.4- 5.3 (4.5- 1.3 (1.0- 1.4 (1.1- 1.2 (1.0- 11.31 11.31 11.77 32.65 32.60 34.2 0.98 0.96 0.98
5.8) 5.9) 5.4) 2.1) 2.2) 1.5) (10.4- (10.40- (11.31- (29.65- (29.40- (30.1- (0.92- (0.92- (0.95-
13.39) 13.13) 13.65) 37.0) 36.8) 37.9) 1.04) 1.04) 1.09)
-344TT 5.1 (4.5- 5.2 (4.5- 4.5 (3.5- 1.2 (1.0- 1.2 (1.0- 1.2 (0.7- 11.31 11.31 13.07 31.80 31.50 33.2 1.0 1.0 1.0
5.9) 6.0) 5.3) 1.7) 1.8) 1.4) (10.27- (10.27- (11.31- (28.10- (28.25- (26.0- (0.94- (0.95- (0.91-
P1
13.13) 13.0) 14.3) 34.90) 35.0) 34.0) 1.09) 1.09) 1.08)
0.67 0.84 0.50 0.48 0.49 0.77 0.13 0.43 0.01* 0.17 0.21 0.33 0.08 0.10 0. 47
1- P -  values for the Kruskal-Wallis test
* means significant association 
NS means not significant
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DISCUSSION
The present study found for the first time 
that the -344C/T polymorphism of the 
CYP11B2 gene is associated with
increased prothrombin time in patients 
with intracerebral hemorrhage. It is known 
a polymorphism that the -344C/T is 
located in the promoter region of the 
CYP11B2 gene and influences the
transcription of aldosterone synthase gene 
and, thus increasing aldosterone 
biosynthesis(3,10). Although the literature 
data on the relationship between
aldosterone and the coagulation system are 
extremely limited, this regulatory peptide 
may be related to the risk of intracerebral 
hemorrhage through several intermediate 
phenotypes of the disease. In particular, 
increased aldosterone levels in carriers of 
the -344TT genotype may increase the risk 
of hemorrhagic stroke through a well- 
recognized mechanism of elevating of
blood pressure. Moreover, aldosterone was 
found to inhibit the activity of endothelial 
nitric oxide synthase(12) and increase 
vascular tone via the upregulation of 
angiotensin II receptors(16) Since 
aldosterone plays a crucial role in 
remodeling of small and large arteries it 
may increase the odds of stroke 
development through enhanced collagen 
synthesis and increased arterial
stiffness(7’13’15). It is also known that 
aldosterone in cooperation with
angiotensin II may cause thrombosis 
through an increased expression of 
plasminogen activator inhibitor-1 in 
endothelial and smooth muscle cells of the 
vessels(6). This means, that increased 
aldosterone levels in carriers of the -344TT 
genotype directly affect the coagulation 
system in these patients, however, the 
mechanisms, by which aldosterone is 
associated with an increased prothrombin 
time are not understood. We cannot 
exclude the possibility that high thrombin 
levels in the patients may be responsible 
for cerebral edema(9) and brain injury(1) 
after intracerebral hemorrhage. In 
conclusion, the present study provides an
evidence that the - 3 4 4 0 T  polymorphism 
of the CYP11B2 may play a role in both 
pathogenesis and course of intracerebral 
hemorrhage, however, further studies are 
required to substantiate such relationships.
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